VS

Vijaysinh Surendrasinh Zala

Active Director Designated Partner DIN 10925088
DIN 10925088 First appointment Jan 2025
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Jan 2025
Shareholding value β€’β€’β€’β€’ Premium profile

About Vijaysinh Surendrasinh Zala

Data last updated:

Vijaysinh Surendrasinh Zala is a Designated Partner at Apicon Pharma Llp (since 2025).

DIN 10925088
Primary Designation Designated Partner
First Appointment 27 Jan 2025
Oldest Company Age 1 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Designated Partner27 Jan 20252025Active

Board colleagues of Vijaysinh Surendrasinh Zala

NameDINCompanyDesignation
Hrishitaba Manmeetsinh Gohil10925089Apicon Pharma LlpDesignated Partner
Manmeetsinh Dharmendrasinh Gohil10925090Apicon Pharma LlpDesignated Partner

Directorship timeline

Open interactive timeline →
Apicon Pharma Llp
Premium access

Shareholding and investment profile for Vijaysinh Surendrasinh Zala

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Vijaysinh Surendrasinh Zala

Vijaysinh Surendrasinh Zala currently holds 1 directorship: Apicon Pharma Llp (Designated Partner, since 27 Jan 2025).

Vijaysinh Surendrasinh Zala was first appointed on 27 Jan 2025 as Designated Partner at Apicon Pharma Llp.

The current boards of Vijaysinh Surendrasinh Zala's companies include Hrishitaba Manmeetsinh Gohil (Apicon Pharma Llp), Manmeetsinh Dharmendrasinh Gohil (Apicon Pharma Llp).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available